Chewed Versus Swallowed Ticagrelor in P2Y12 Inhibitor-Naïve Patients Undergoing Percutaneous Coronary Intervention

• DOI: 10.17294/2330-0698.2009
• Publication Date: 2023-04-18T17:15:01Z
• Authors: Thomas F Wilson; Muddasir Ashraf; M. Fuad Jan; Tonga Nfor; Louie Kostopoulos; Joaquin Solis; Jayant Khitha; Ahmad Khraisat; Anthony C DeFranco; Tanvir Bajwa; Suhail Q Allaqaband
• Keywords: non-st-segment; Surgical Procedures; non-ST-segment; Cardiology; R; Therapeutics; Medical Pharmacology; Operative; antiplatelet medication; 3. Good health; acute coronary syndrome; ticagrelor; loading dose; P2Y12 reaction units; Cardiovascular Diseases; Medicine and Health Sciences; p2y12 reaction units; Medicine; Surgery; Patient Safety; stable ischemic heart disease; Other Chemicals and Drugs

Purpose: Dual antiplatelet therapy is standard for patients undergoing percutaneous coronary intervention (PCI) with stents. Traditionally, swallow the loading dose of a P2Y12 inhibitor before or during PCI. Time to achieve adequate platelet inhibition after swallowing varies significantly. Chewed tablets may allow more rapid aggregation. However, data this strategy in stable ischemic heart disease non-ST-elevation acute syndrome (NSTE-ACS) are less robust.